1 active not recruiting, 1 not yet recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Ra223: new trials by email Literature Review of Ra223 trials Research Report on Ra223
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer Ra223, Darolutamide Oral Tablet, Androgen Deprivation Therapy (ADT) - Metastatic Hormone-Sensitive Prostate Cance | Phase 2 | Not yet recruiting | Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD | 50 | 2026-09-01 | 2026-07-21 |
| Phase III Radium 223 mCRPC-PEACE III Ra223, Enzalutamide - Prostate Cancer | Phase 3 | Active not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 446 | 2015-10-01 | 2025-09-19 |
Prostatic Neoplasms (2) · Neoplasm Metastasis (1)
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD (1) · European Organisation for Research and Treatment of Cancer - EORTC (1)
Spain (2) · Belgium (1) · Brazil (1) · Canada (1) · Denmark (1) · France (1) · Ireland (1) · Italy (1) · Norway (1) · Poland (1) · Switzerland (1) · United Kingdom (1)
Bertrand Tombal, Prof (1) · David Lorente, M.D., Ph.D. (1) · Guillermo de Velasco, M.D., Ph.D. (1) · Silke Gillessen, Prof (1)
2014 (1)